KURA vs. TARO, AVDL, ZLAB, DVAX, AKRO, PTGX, MORF, SUPN, SDGR, and XNCR
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Taro Pharmaceutical Industries (TARO), Avadel Pharmaceuticals (AVDL), Zai Lab (ZLAB), Dynavax Technologies (DVAX), Akero Therapeutics (AKRO), Protagonist Therapeutics (PTGX), Morphic (MORF), Supernus Pharmaceuticals (SUPN), Schrödinger (SDGR), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.
Taro Pharmaceutical Industries (NYSE:TARO) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
91.4% of Taro Pharmaceutical Industries shares are owned by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Comparatively, 5.5% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Taro Pharmaceutical Industries presently has a consensus target price of $43.00, indicating a potential upside of 1.65%. Kura Oncology has a consensus target price of $28.28, indicating a potential upside of 36.54%. Given Taro Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Kura Oncology is more favorable than Taro Pharmaceutical Industries.
Taro Pharmaceutical Industries has a net margin of 7.48% compared to Taro Pharmaceutical Industries' net margin of 0.00%. Kura Oncology's return on equity of 3.26% beat Taro Pharmaceutical Industries' return on equity.
Taro Pharmaceutical Industries has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Kura Oncology received 113 more outperform votes than Taro Pharmaceutical Industries when rated by MarketBeat users. Likewise, 68.90% of users gave Kura Oncology an outperform vote while only 61.80% of users gave Taro Pharmaceutical Industries an outperform vote.
In the previous week, Kura Oncology had 5 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 9 mentions for Kura Oncology and 4 mentions for Taro Pharmaceutical Industries. Kura Oncology's average media sentiment score of 0.67 beat Taro Pharmaceutical Industries' score of 0.52 indicating that Taro Pharmaceutical Industries is being referred to more favorably in the media.
Taro Pharmaceutical Industries has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Summary
Taro Pharmaceutical Industries beats Kura Oncology on 10 of the 17 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
